Author Archives: admin


I took an international trip with my frozen eggs to learn about the fertility industry – MIT Technology Review

Depending on whats being carried and how much they can pay, the patient or patients involved will choose either a hand-carry service, a commercial carrier such as DHL or FedEx, or something in between, such as the combination of commercial flights and local couriers that Loewen relied on during the pandemic. The cost of transporting my eggs with FlyVet Europa was 1,300 euros, or about $1,400 at the time. That includes the price of two one-way tickets for Paolo and the egg suitcase, and a few incidental expenses. (When I told Monaco how many eggs were traveling, he quipped, Uno squadro di calcio!a soccer team.)

CryoStork, the division of Cryoport devoted to the fertility sector, offers all three tiers of servicecommercial carriers for something that can be easily replaced (sperm, in other words), a middle-tier service using local couriers and air freight, and a door-to-door hand-carry servicefor prices ranging from a few hundred dollars to as much as $7,000 or $8,000 for an international hand-carry trip.

Ultimately, the pandemic boosted business for Loewen. Today, he and a team of eight colleagues, half employees and half working on a per-shipment basis, handle around 30 to 40 IVF-related shipments each month. Similarly, when the war in Ukraine began, Loewen and other colleagues received frantic requests from clients desperate to move their biomaterials out of the capital, Kiev, where most of the countrys IVF clinics and surrogacy agencies are based, and business shifted to nearby Georgia. But by September, Loewen was planning to once again deliver biomaterials to Ukraine. People want to have babiesconflict or not, he says.

What does it take to be a tissue courier, and how does one get into the field? Everyone I spoke to said that to succeed, you must love traveling, have a calm personality (in case, as happened to Loewen, youre ever surrounded by a knot of armed Belarusian soldiers at the airport and accused of trafficking human organs), and be adept at problem-solving.

Loewen looks for people with experience in the travel sector, who can navigate new cities and wont be rattled by a flight cancellation or a grumpy customs official. Mark Sawicki of Cryoport has several former pilots now working as couriers; their security clearances enable them to move through airports more easily than civilians.

Nicole Dorman, 43, has always loved children; she jokes that her current job as a courier is babysitting. She has three kids, aged 14 to 22, and has been a teachers aide and a school crossing guard, following four years in the US Army. When shes home for a week or two at a time with her kids in between gigs, she also makes deliveries for DoorDash in Clarksville, Tennessee.

WENN RIGHTS LTD / ALAMY STOCK PHOTO

Dorman had begun by transporting stem cells for a Frankfurt-based courier service. When she was looking for work in November of 2020, she emailed a half-dozen IVF courier companies and heard back from Loewen within 15 minutes. She has been working for him ever since, and also does US shipments for the Ukrainian company ARK Cryo, as well as EmbryoPort, a UK-based firm.

Dorman is on the road roughly 70% of each month; when we spoke in mid-May, she was preparing for a weeklong trip beginning with a pickup in Indianapolis, a drop-off in Bratislava, a train ride from there to Prague for another pickup, and then a flight to Greece. Like all couriers whove been working for any length of time, she has frequent flier status. In the 18 months since she started, she has transported more than 90 shipments. Now I can pretty much do it in my sleep, she says.

See the original post:
I took an international trip with my frozen eggs to learn about the fertility industry - MIT Technology Review

External Beam Radiation Therapy Market: Growing Awareness about Early Detection and Diagnosis of various Cancer Types to Drive the Market – BioSpace

Wilmington, Delaware, United States, Transparency Market Research Inc. The accelerating rate of cancer cases worldwide is considered the chief factor augmenting the growth of the global external beam radiation therapy market. The rapid advancements in medical technology and the growing awareness about early detection and diagnosis of various cancer types will also boost this markets growth in the coming years.

External beam radiotherapy or EBRT is considered very common among radiotherapy types. Rather than brachytherapy (fixed source radiotherapy) and unlocked source radiotherapy, in which the radiation source is inside the body, external beam radiotherapy coordinates the radiation at the tumor from outside the body.

Request Brochure of Report https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=64928

Malignancy or in simpler terms, cancer is a genuine medical issue influencing a huge populace across the globe. Analysis at a beginning phase and therapy for malignant growth, as it influences the insusceptible framework, is a test for medical services suppliers. External radiation is normally done during outpatient visits to an emergency clinic or therapy focus. The vast majority get external radiation therapy over numerous weeks.

In any case, a few groups may have to go to the treatment community two times every day for a less number of weeks. Radiation innovation permits cautious conveyance of external beam radiation therapy. These machines center the radiation around the specific area on the body with the goal that ordinary tissues are influenced as little as could really be expected.

Request for ToC https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=64928

Global External Beam Radiation Therapy Market: Overview

External radiation (or external beam radiation) is the most common type of radiation therapy used for cancer treatment. A machine is used to aim high-energy rays (or beams) from outside the body into the tumor.

Radiation technology allows very careful delivery of external beam radiation therapy. These machines focus the radiation on the exact location on the body so that normal tissues are affected as little as possible.

External radiation is usually done during outpatient visits to a hospital or treatment center. Most people undergo external radiation therapy over many weeks. Usually, patients visit the treatment center every weekday for a certain number of weeks. However, some people may need to go to the treatment center twice a day for a fewer number of weeks.

Key Driver of Global External Beam Radiation Therapy Market

The global external beam radiation therapy market is growing at a rapid pace owing to increase in incidence of cancer

Cancer is a serious health problem affecting a large population across the globe. Diagnosis at an early stage and treatment for cancer, as it affects the immune system, is a challenge for health care providers. According to the WHO, 18 million new cancer cases were reported in 2018 across the world, and cancer causes around 8.2 million deaths annually. Moreover, the number of cancer cases is likely to rise by 70% across the globe, with 60% of cases in Africa, Asia, and Latin America.

Request for Report Methodology https://www.transparencymarketresearch.com/sample/sample.php?flag=RRM&rep_id=64928

Key Restraint of Global External Beam Radiation Therapy Market

According to WHO report, an estimated two-thirds of the planet does not have access to basic radiology services. Kenya has only 200 radiologists for 43 million people. People in Nepal travel more than two days to find a facility with an X-ray and spend a months income for that. Increase in gap between radiologists and people restrains the global radiation therapy management market.

North America to Account for Major Share of Global External Beam Radiation Therapy Market

In terms of region, the global external beam radiation therapy market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa

North America is projected to dominate the global market during the forecast period. This is attributed to an increase in number of patients. Moreover, well-established health care infrastructure, presence of key players, and favorable reimbursement policies are anticipated to drive the market in the region.

Make an Enquiry Before Buying https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=64928

Key Players Operating in Global External Beam Radiation Therapy Market

Major players operating in the global external beam radiation therapy market include:

More Trending Reports by Transparency Market Research

Erectile Dysfunction Drugs Market: The global erectile dysfunction (ED) drugs market is expected to reach the value of US$ 2.5 Bn by the end of 2028.

Regulatory Affairs Outsourcing Market: The global regulatory affairs outsourcing market is expected to reach the value of US$ 17.3 Bn by the end of 2028.

Digital Health Market: The global digital health market is expected to cross the value of US$ 1.2 Trn by the end of 2028.

Equine Healthcare Market: The global equine healthcare market is expected to cross the value of US$ 972.8 Mn by the end of 2028.

Stem Cells Market: The global stem cells market is expected to reach the value of US$ 25.68 Bn by the end of 2028.

Medical Imaging Equipment Market: The global medical imaging equipment market is expected to reach the value of US$ 50.3 Bn by the end of 2028.

Home Healthcare Market: The global home healthcare market is expected to reach the value of US$ 499.6 Bn by the end of 2028.

Triclabendazole Market: The global triclabendazole market is expected to reach the value of US$ 632.1 Mn by the end of 2031.

About Us

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, providescustom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update -https://www.youtube.com/channel/UC8e-z-g23-TdDMuODiL8BKQ

Contact

Rohit Bhisey Transparency Market Research Inc. CORPORATE HEADQUARTER DOWNTOWN, 1000 N. West Street, Suite 1200, Wilmington, Delaware 19801 USA Tel: +1-518-618-1030 USA Canada Toll Free: 866-552-3453 Website: https://www.transparencymarketresearch.com

Blog: https://tmrblog.com

Email: sales@transparencymarketresearch.com

See original here:
External Beam Radiation Therapy Market: Growing Awareness about Early Detection and Diagnosis of various Cancer Types to Drive the Market - BioSpace

Todos Medical Announces NFL Hall of Famer Michael Irvin as Tollovid™ Sports Ambassador for #TolloUp Campaign

NEW YORK, NY and Tel Aviv, ISRAEL, Sept. 16, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that Michael Irvin has agreed to become the Sports Ambassador for the Company’s 3CL Pharma’s majority-owned subsidiary’s #TolloUp marketing campaign for 3CL protease inhibitor immune support supplement Tollovid™. A recent market research study showed that 90%+ of both acute infection and Long COVID customers indicated they benefitted from Tollovid™. Tollovid has been Informed Sports certified as not having any performance enhancing or banned substances and is safe for athletes to use while competing.

Read the original post:
Todos Medical Announces NFL Hall of Famer Michael Irvin as Tollovid™ Sports Ambassador for #TolloUp Campaign

ORYZON to Present Preliminary Blinded Aggregate Safety Data From Vafidemstat’s Ongoing Phase IIb PORTICO Trial in Borderline Personality Disorder

MADRID, Spain and BOSTON, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today presents initial preliminary blinded aggregate safety data from its ongoing Phase IIb PORTICO trial, investigating vafidemstat in Borderline Personality Disorder (BDP), in a oral communication at the 10th European Conference on Mental Health (ECMH), being held in Lisbon (Portugal) on September 13-16.

View original post here:
ORYZON to Present Preliminary Blinded Aggregate Safety Data From Vafidemstat’s Ongoing Phase IIb PORTICO Trial in Borderline Personality Disorder

Pfizer and BioNTech Receive Positive CHMP Opinion for Conversion of COMIRNATY® Conditional Marketing Authorization to Full Marketing Authorization in…

NEW YORK and MAINZ, GERMANY, September 16, 2022 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended converting the conditional Marketing Authorization (cMA) for COMIRNATY® [COVID-19 Vaccine (nucleoside modified)] to standard (also referred to as “full”) Marketing Authorization (MA) for all authorized indications and formulations. The European Commission (EC) will review the CHMP recommendation and is soon expected to make a final decision.

Read more here:
Pfizer and BioNTech Receive Positive CHMP Opinion for Conversion of COMIRNATY® Conditional Marketing Authorization to Full Marketing Authorization in...

Belite Bio Receives Approval of LBS-008 Phase 3 Clinical Trial in China

SAN DIEGO, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a San Diego based clinical stage biopharmaceutical drug development company targeting currently untreatable eye diseases, today announced the approval from the National Medical Products Administration (NMPA) of China to initiate the Phase 3 clinical trial of LBS-008 in adolescent STGD1 in China.

See the original post:
Belite Bio Receives Approval of LBS-008 Phase 3 Clinical Trial in China

Wave Life Sciences to Host Analyst and Investor Virtual Event, “Towards the Clinic: Spotlight on RNA Editing for AATD,” on September 28, 2022

Focus on WVE-006, a first-in-class RNA editing development candidate for AATD, and feature AATD expert presentation Focus on WVE-006, a first-in-class RNA editing development candidate for AATD, and feature AATD expert presentation

See the original post:
Wave Life Sciences to Host Analyst and Investor Virtual Event, “Towards the Clinic: Spotlight on RNA Editing for AATD,” on September 28, 2022

Benitec Biopharma Inc. Announces Closing of $18 Million Underwritten Public Offering

HAYWARD, Calif., Sept. 16, 2022 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced it closed its previously announced underwritten public offering of 29,809,471 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying warrants to purchase up to 29,809,471 shares of common stock. Each share of common stock (or pre-funded warrant in lieu thereof) was sold together with one common warrant to purchase one share of common stock at a combined offering price of $0.60. The warrants will be exercisable commencing on the effective date of an increase in our authorized shares of common stock at an exercise price of $0.66 per share of common stock and will expire on the fifth anniversary of such initial exercise date.

Here is the original post:
Benitec Biopharma Inc. Announces Closing of $18 Million Underwritten Public Offering

Myovant Recognizes Prostate Cancer Awareness Month with Educational Sponsorships and Online Campaign to Encourage Patients to Speak Up, Seek Support…

Peer Video Series Campaign and Educational Sponsorships Spotlight Patient Barriers to Conversations Peer Video Series Campaign and Educational Sponsorships Spotlight Patient Barriers to Conversations

Read more from the original source:
Myovant Recognizes Prostate Cancer Awareness Month with Educational Sponsorships and Online Campaign to Encourage Patients to Speak Up, Seek Support...

Revolo Biotherapeutics to Participate in the Sachs Associates 22nd Annual Biotech in Europe Forum for Global Partnering and Investment

NEW ORLEANS and LONDON, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, today announced that it will be participating in the Sachs Associates 22nd Annual Biotech in Europe Forum for Global Partnering and Investment taking place in Basel, Switzerland from September 21-22.

Follow this link:
Revolo Biotherapeutics to Participate in the Sachs Associates 22nd Annual Biotech in Europe Forum for Global Partnering and Investment